与免疫检查点抑制剂和用于减轻出血风险的新型抗血栓策略相关的血栓事件
Jiayi Chen1, Shuang Liu1, Zheng Ruan1
1Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, Collaborative Innovation Center of Hematology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
Blood reviews
|June 14, 2024
概括
免疫检查点抑制剂增加了癌症患者的血栓事件. 针对血小板激活的新型抗血小板疗法可能提供双重抗血栓和抗瘤益处,降低出血风险.
科学领域:
- 在瘤学瘤学.
- 血液学 血液学 血液学
- 药理学 药理学是指药理学的学科.
背景情况:
- 晚期癌症患者面临着不良的预后,通常因血栓事件而复杂化.
- 免疫检查点抑制剂 (ICI) 增加了动脉样硬化血栓事件的风险.
- 血小板在血栓形成和癌症进展中起着至关重要的作用.
研究的目的:
- 审查与ICI治疗相关的血栓形成.
- 探索血小板激活在癌症进展中的作用.
- 检查具有潜在抗血小板和抗瘤作用的新型抗血小板疗法.
主要方法:
- 文献综述侧重于免疫疗法,血栓形成和血小板功能.
- 对ICI相关血栓形成背后的机制的分析.
- 评估新兴的抗血小板标及其双重作用潜力.
主要成果:
- 抗血小板感染与血栓形成风险增加有关,因此需要采取抗血小板策略.
- 血小板激活是癌症进展的多个阶段的组成部分.
- 新型抗血小板药物显示出有前途的,可以在没有显著出血的情况下控制血栓形成.
结论:
- 针对血小板激活提供了一个有希望的策略,在免疫治疗期间管理与癌症相关的血栓形成.
- 新的抗血小板疗法可能会提供双重的抗血小板和抗瘤益处.
- 对这些新型药物的进一步研究是有必要的,以优化癌症患者的治疗结果.
相关概念视频
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
517
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
517
Anticoagulant Drugs: Low-Molecular-Weight Heparins
675
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
675
Disorders of Hemostasis
831
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
831
Esophageal Varices-II: Clinical Features and Management
57
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
57
Extrinsic and Intrinsic Pathways of Hemostasis
7.1K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
7.1K


